61 results
ARS
2023 FY
MYGN
Myriad Genetics, Inc.
17 Apr 24
Annual report to shareholders
4:33pm
disease risk or reduce risk of cancer recurrence. The MyRisk Genetic Test Result and MyRisk Management Tool® summarize medical society guidelines
8-K
EX-99.1
MYGN
Myriad Genetics, Inc.
27 Feb 24
Results of Operations and Financial Condition
4:05pm
, as President & Chief Clinical Officer of Oncology, effective March 18, 2024.
In January 2024, the American Society of Clinical Oncology (ASCO)—Society
ARS
2022 FY
MYGN
Myriad Genetics, Inc.
12 Apr 23
Annual report to shareholders
4:10pm
Management Tool® summarize medical society guidelines for managing a patient with a genetic mutation in view of their personal and family history of cancer
8-K
EX-99.1
w5sl05b7 74l
4 Aug 22
Myriad Genetics Reports Second Quarter Financial Results
7:06am
8-K
EX-99.1
tbyut
11 Jan 22
Results of Operations and Financial Condition
4:16pm
8-K
EX-99.1
17iqljg5415ikjmz3s
3 May 21
Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives
4:05pm
10-KT
nrnnwpaf6e
16 Mar 21
Annual report (with FYE transition)
2:24pm
8-K
EX-99.1
2wmh2ry4rtu
13 Aug 19
Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results
4:11pm
8-K
EX-99.1
oq6n sas80
7 May 19
Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results
5:09pm
8-K
EX-99.1
ubers9jqj0zvii6d
14 Mar 19
Myriad’s myPath® Melanoma Test Receives Medicare Coverage
8:52am